Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Future directions: microcirculation under inflammation

Future directions: microcirculation under inflammation

Making microcirculatory assessment usable at the bedside, and finding out whether treating it changes anything.

Microcirculation and microvascular function

From observation to intervention

The decisive open question is whether targeting the microcirculation improves outcomes. Microcirculatory abnormality predicts poor outcome, but prediction is not a treatment target, and no intervention has been shown to improve outcome by correcting microcirculatory flow specifically.

Trials resolving this require a usable bedside measure, an intervention that reliably alters it, and an outcome that matters — and the first of those is only recently approaching practicality.

Automated analysis

Manual analysis of videomicroscopy was the main barrier to clinical use. Automated and semi-automated software returning indices in near real time is the development that would make microcirculation-guided resuscitation testable at all.

Glycocalyx-directed therapy

Protecting or restoring the glycocalyx is an identified target, with candidate approaches including modified fluid strategies and agents limiting shedding. None is established, and the field should be read as preclinical and early translational.

Beyond sepsis

The same mechanisms are implicated in diabetes, chronic kidney disease, hypertension, long-term consequences of severe infection, and perioperative organ injury. Whether microvascular dysfunction is a common final pathway across these, and whether it is modifiable, is a broader and longer-term question.

Methodological needs

Standardised acquisition and analysis protocols so values are comparable between centres. Agreed thresholds for abnormality. Core outcome sets. Without these, a literature of small single-centre studies using different techniques cannot be synthesised.

In short

What to take from this.

  • No intervention is established to improve outcome via the microcirculation.
  • Automated analysis is the enabling step for clinical trials.
  • Read glycocalyx therapeutics as preclinical, not clinical.

Sources

  • Consensus guidance on microcirculation assessment and reporting
  • Translational literature on glycocalyx protection

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.